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Abstract 
Background & Aims: Colonoscopy examination does not always detect colorectal cancer 
(CRC)— some patients develop CRC after negative findings from an examination. When this 
occurs before the next recommended examination, it is called interval cancer. From a 
colonoscopy quality assurance perspective, that term is too restrictive, so the term post-
colonoscopy colorectal cancer (PCCRC) was created in 2010. However, PCCRC definitions and 
methods for calculating rates vary among studies, making it impossible to compare results. We 
aimed to standardize the terminology, identification, analysis and reporting of PCCRCs and 
CRCs detected after other whole-colon imaging evaluations (post-imaging colorectal cancers; 
PICRCs). 
 
Methods: A 20-member international team of gastroenterologists, pathologists and 
epidemiologists; a radiologist; and a non-medical professional met to formulate a series of 
recommendations, standardize definitions and categories (to align with interval cancer 
terminology), develop an algorithm to determine most-plausible etiologies, and develop 
standardized methodology to calculate rates of PCCRC and PICRC. The team followed the 
Appraisal of Guidelines for Research and Evaluation II tool. A literature review provided 401 
articles to support proposed statements; evidence was rated using the GRADE system. The 
statements were voted on anonymously by team members, using a modified Delphi approach.  
 
Results: The team produced 21 statements that provide comprehensive guidance on PCCRC and 
PICRCs. The statements present standardized definitions and terms, as well as methods for 
qualitative review, determination of etiology, calculation of PCCRC rates, and non-colonoscopic 
imaging of the colon. 
 
Conclusions: A 20-member international team has provided standardized methods for analysis 
of etiologies of PCCRCs and PICRCs and defines its use as a quality indicator. The team 
provides recommendations for clinicians, organizations, researchers, policy makers, and patients. 
KEY WORDS: quality measures; AGREE II; colonoscopy; CT colonography 
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1. INTRODUCTION 
 
Although colonoscopy is pivotal for the diagnosis and prevention of colorectal cancer (CRC), cancers may 
be diagnosed months or years after a colonoscopy that is negative for CRC or CRC precursor lesions. 
To prevent CRC, a colonoscopist must both detect the premalignant polyps and resect them completely
1, 
2
. Post-colonoscopy CRCs (PCCRCs), i.e. cancers diagnosed after a colonoscopy in which no cancer was 
found, may arise from missed cancers, and missed or incompletely resected benign lesions 
3-11
. The 
proportion of PCCRCs detected shortly after the exam that arise from rapidly progressing pre-cancerous 
polyps (new cancer or accelerated biology-related cancer), remains to be determined, but is certainly 
low
12
. Reasons for missed lesions include inadequate bowel preparation and colonoscopist-dependent 
factors such as incomplete colonoscopy, short cecal withdrawal time and suboptimal inspection 
technique
6, 13, 14
. Adenoma miss rates and incomplete polypectomy rates vary between colonoscopists,
15-
17
 and patients of colonoscopists with low ADRs have higher interval cancer rates
14, 18
.  
These findings indicate opportunities for improved colonoscopy performance, for using cancer 
appearing after a negative colonoscopy as an important benchmark for quality, and for standardizing 
methodologies to allow more direct comparisons between services
19
.  
 
2. AIM 
 
The literature on PCCRC diagnosed after a colonoscopy in which no cancer was found lacks agreement 
on terminology, methodology or analysis of causation. We recently published guidance on the screening 
term “interval cancer”
7
 (which may or may not relate to colonoscopy) – however these two terms are 
not synonymous, as shall be described later, and no standardized performance measure guidelines exist. 
To address these concerns, the World Endoscopy Organization (WEO) convened a working group to use 
an evidence-based consensus process to make recommendations for future investigators, policy-
makers, clinical services and patients. 
The aims of the PCCRC project were: 
1. To standardize terminology and definitions relating to PCCRC 
2. To describe the relationship between PCCRC terminology and interval cancer terminology 
3. To standardize the categorization of the potential explanations for PCCRC occurrence 
4. To create colonoscopy, histology and radiology minimum datasets to facilitate PCCRC analysis 
5. To develop a standardized definition for a PCCRC rate performance measure and a standardized 
methodology for its calculation, thus allowing benchmarking and comparison between services 
6. To recommend appropriate action for services in the monitoring and review of PCCRC cases and 
PCCRC rates 
7. To consider whether the PCCRC concept can be extended to radiological colorectal imaging 
8. To provide a research manuscript checklist for authors and peer-reviewers of PCCRC papers 
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3. METHODOLOGY 
 
Our methodology was based on The Appraisal of Guidelines for Research and Evaluation (AGREE II) 
tool
20
. A multidisciplinary team of international experts was selected, including gastroenterologists, 
pathologists, epidemiologists, a radiologist and a patient representative, to ensure wide range of 
expertise and broad representation to cover all aspects of our topic.  
The approach taken was to: 
1. Determine the purpose of having a performance measure of PCCRC to align recommendations 
with purpose and the rationale for such 
2. Develop a series of key questions relating to PCCRC  
3. Conduct a systematic literature search of these questions 
4. Formulate a set of recommendations using a modified Delphi consensus approach 
 
The Core (initial) group consisted of 14 members (13 voting and one non-voting). Members were then 
allocated to two Working Groups, on the etiology of PCCRCs and performance of PCCRC rates in 
colonoscopy and radiology practice. Key questions were compiled by the project writing group.  
Each working group addressed the following key questions: 
1. Etiology Working Group (7 members, one of whom participated in both groups) 
a. Which terminology should be used to describe etiology categories? 
b. What are the risk factors and possible explanations of PCCRC? 
c. How should we ascribe possible explanations? 
d. What should be the minimum colonoscopy, histology and radiology dataset to examine 
PCCRC? 
e. What molecular tests should be performed to examine PCCRC? 
f. How to prevent PCCRC in high-risk groups? 
2. Performance Working Group (8 members, one of whom participated in both groups) 
a. How should PCCRCs be calculated & reported? 
b. How should PCCRC rates be monitored? 
c. How should PCCRC papers be peer-reviewed? 
d. Radiology – can we, and how do we extend the methodology to post-imaging CRC? 
A comprehensive literature search was performed in PubMed and Cochrane databases, for articles 
published in English language from 2006 until present (see online supplementary material for details) 
which ultimately provided 402 articles providing background and supporting the statements. We limited 
our search to articles from 2006 and later, aiming for our database to reflect current practice. All 
members were asked to and added other key references during the consensus process. 
Each working group provided initial draft statements, along with supporting text and suggested 
references, related to their respective sub-topic; each member voted anonymously, via electronic 
correspondence, on the resulting 33 statements, using an agreement scale of 1 (strongly agree) to 5 
(strongly disagree). A modified Delphi process was followed, with consensus requiring at least 80% 
agreement. In areas of continuing disagreement, a recommendation for or against a particular 
statement (compared with a specific alternative) required both >50% of participants in favor and <20% 
preferring the comparator. Failure to meet this criterion resulted in no recommendation. 
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Following votes and comments, statements were iteratively added, and others reduced or merged. Prior 
to the second voting round, the group added 7 additional international experts for a total of 20 voting 
members plus a non-voting patient representative who provided input during the rest of the consensus 
process. Ultimately, statements achieved consensus after a fourth, final voting round (Figure 1). 
The GRADE system for rating quality of evidence and strength of recommendations was utilised during 
statement development (Table 1). The GRADE tool separates the strength of evidence from the strength 
of recommendation
21
.  
 
4. STATEMENTS & EVIDENCE 
 
TERMINOLOGY & DEFINITIONS 
 
Statement 1. We recommend that Post-Colonoscopy Colorectal Cancer (PCCRC) is the preferred term 
for cancers appearing after a colonoscopy in which no cancer is diagnosed. 
GRADE of evidence: very low; Strength of recommendation: strong. 
 
Statement 2. PCCRCs can be sub-categorized into: 
• Interval cancers (where the cancer is identified before the next recommended screening or 
surveillance examination) 
• Non-interval cancers (where the cancer is identified at [type A] or after [type B] a 
recommended screening or surveillance interval, or where no subsequent screening or 
surveillance interval for repeat examination was recommended [type C], up to 10 years 
following the colonoscopy) 
 GRADE of evidence: very low; Strength of recommendation: strong. 
The term “interval cancer” is primarily a screening and surveillance term; its precise definition is a CRC 
diagnosed after a colorectal screening examination or test in which no cancer is detected, and before 
the date of the next recommended exam
7
. Whilst this is an important definition for screening and 
surveillance programs, this terminology does not fit precisely with all that is required for colonoscopy 
quality assurance (QA) purposes. Many colonoscopy procedures, particularly diagnostic procedures, do 
not result in a recommendation for a further colonoscopy, and therefore there is no “interval”. While 
from a screening program perspective, a cancer found at a subsequent screening colonoscopy is a 
screening “success” and not an interval cancer by definition
7
, from a colonoscopy quality point of view, 
study of these procedures is worthwhile as there might have been a missed opportunity to identify a 
cancer or identify/fully resect a pre-cancerous lesion at the prior exam. Furthermore, interval cancers 
may arise from non-colonoscopic aspects of a screening program (for example after a negative fecal 
occult blood test).  For these reasons, the term “Post-colonoscopy colorectal cancer” (PCCRC), first 
coined in 2010, is recommended as an all-encompassing, overarching term (see table 2)
9
.  
PCCRCs can be subcategorized into true interval cancers, i.e. those identified prior to the next 
recommended screening or surveillance examination, and non-interval cancers. Non-interval cancers 
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may be further subcategorized into those that occur at or after a recommended screening or 
surveillance interval, and those where no subsequent screening or surveillance procedure was 
recommended. The interval cancer subcategory will usually be a measure of quality of the colonoscopy, 
as it presumes that the recommended surveillance interval will pre-empt the occurrence of CRC before 
the next planned procedure. The non-interval cancer subcategory may similarly be a measure of quality 
of the colonoscopy but may also reflect the “correctness” or appropriateness of the current screening or 
surveillance interval recommendations (for cancers occurring at or after the recommended surveillance 
interval) or the wisdom of a “once-only” screening colonoscopy recommendation itself (for cancers 
occurring without any repeat exam having been planned). 
Examples of PCCRCs subcategories are provided in table 2. This categorisation may aid discussions as to 
potential quality implications and learning points from a case; for example, a non-interval PCCRC type B 
could be because of poor adherence to surveillance intervals, or due to an incomplete surveillance 
colonoscopy due to suboptimal preparation or an incomplete exam, leading to delays in cancer 
diagnosis. 
We should also stress that cancers for which colonoscopy is not considered “gold standard” for their 
diagnosis (for example, neuroendocrine tumours, or squamous cell carcinomas of the anorectum) are 
not included in the PCCRC nomenclature. 
QUALITATIVE REVIEW OF PCCRC CASES 
 
This section outlines the recommended methodology for assessing an individual PCCRC case. 
 
Statement 3. We recommend that services implement a formal process to identify and register PCCRC 
cases, so they can be reviewed for potential causative factors. Ideally this should be on a prospective 
basis, by reviewing whether each newly diagnosed CRC may be a PCCRC. If such methodology is not 
feasible, then the service should perform an annual retrospective review of all CRC cases diagnosed in 
the last year. 
GRADE of evidence: very low; Strength of recommendation: strong. 
Statement 4. We recommend that services perform a Root Cause Analysis (see table 3) of every PCCRC 
case identified, to determine the most plausible explanation for the PCCRC, and where appropriate to 
identify and implement changes in practice to improve performance, monitoring them for 
effectiveness. 
GRADE of evidence: very low; Strength of recommendation: strong. 
Root Cause Analysis (RCA) of PCCRC cases helps to identify shortcomings in quality that might be 
correctable, for potential performance management (Table 3)
6, 7
. 
To achieve this, robust methods to capture and analyze PCCRC cases should be established. Ideally this 
should be performed prospectively (i.e. by reviewing each CRC case as it is diagnosed). Where this is not 
possible, regular audits of all new CRC cases should be performed; we suggest this occurs at least 
annually and includes all prior colonoscopy history for every new CRC case. 
Because PCCRCs are relatively infrequent, it is important that the learning from RCA, and potential 
changes in practice, be shared not only with the relevant endoscopist, but with all colonoscopists in the 
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service. A proposed RCA checklist is illustrated in Table 3. As seen in the checklist, we recommend that 
individual cases are assessed as being screen-related or not.  
Statement 5. We suggest the use of the term “most plausible explanation” when describing the 
etiology of PCCRC cases, given the inherent uncertainties in this process. 
Determining the precise etiology of a PCCRC is challenging given current uncertainties about cancer 
biology (e.g. the mean sojourn time from polyp to cancer due to multiple pathways to cancer initiation 
and progression). Potential factors for PCCRCs include whether the precursor lesion was “undetected” 
or “detected but not resected” and whether an a priori visualized lesion was completely resected
22-26
. 
Given these uncertainties, we suggest the use of the term “most plausible explanation” when describing 
the etiology of PCCRC cases. 
GRADE of evidence: very low; Strength of recommendation: weak 
 
Statement 6 To facilitate the use of a common language when categorising PCCRCs according to their 
most plausible explanations, we suggest that the following categories should be used: 
• Possible missed lesion, prior examination adequate 
• Possible missed lesion, prior examination negative but inadequate 
• Detected lesion, not resected 
• Likely incomplete resection of previously identified lesion 
• Likely new CRC 
 
Disclaimer: Categorization of PCCRCs according to their most plausible explanations should be used to 
facilitate QA work or research. This categorization should NOT be used to define accountability at 
individual level or as a measure to define or support medico-legal decision making. 
 
We suggest that the following descriptors should be used when the following parameters are met (see 
figure 2):  
 
a. Most plausible explanations “Possible missed lesion, prior examination adequate”  
• Colonoscopy within the last 4 years that did not detect cancer, where: 
o no advanced adenoma (AA, i.e. ≥1cm in size and/or villous and/or containing high-
grade dysplasia) was identified in the same bowel segment; and 
o there is evidence of cecal intubation; and 
o adequate bowel prep was documented 
 
b. Most plausible explanation “Possible missed lesion, prior examination negative but inadequate”  
• Colonoscopy within the last 4 years that did not detect cancer, where: 
o no AA was identified in the same bowel segment 
o but where either: 
 cecal intubation was not achieved/documented; or 
 bowel prep was inadequate 
 
c. Most plausible explanation “Detected lesion, not resected” 
• Colonoscopy within the last 4 years that did not detect cancer, where: 
o AA was identified in the same bowel segment and 
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o The lesion was not resected 
  
d. Most plausible explanation “Likely incomplete resection of previously identified lesion”  
• Colonoscopy within the last 4 years that did not detect cancer, where: 
o AA was resected from the same bowel segment and 
o there was no endoscopic/histological confirmation of complete resection 
 
e. Most plausible explanation “Likely new cancer”  
o Last colonoscopy > 4 years prior to CRC detection 
 
In addition to the above five categories, we suggest adding the modifying statement “deviation from 
the planned management pathway” when there is clear evidence of deviation from the planned 
management pathway. For example, where a polyp was identified at colonoscopy, with a plan to 
remove at a later date, which never happened.  
GRADE of evidence: low; Strength of recommendation: weak.  
Definitions of these scenarios vary in the literature (see Table 4), highlighting a need for uniform 
terminology.
22-24, 26
 Here, we provide our consensus-based categorization construct. 
We recognise this construct has not been validated, is influenced by the time of observation (e.g. with 
longer follow-up, a higher percentage of PCCRCs will be designated as new cancers), that certain cases 
might not fit neatly into one of the 4 categories, and the potential for misclassification. For example, a 
PCCRC after a colonoscopy 5 years ago that resected an advanced adenoma would be assigned to “likely 
new cancer”, however, a plausible alternative is that this PCCRC arose from incomplete resection of the 
adenoma.  Alternatively, a PCCRC attributed to incomplete resection could also result from a different 
missed synchronous lesion located in the same segment. 
Other algorithms that have adjudicated “missed” cancers have used 30 months and 36 months as a cut-
off
27
, although natural history studies of the polyp-to-cancer sequence generally support longer time 
frames. For example, microsimulation modelling estimated that the mean dwell time (from normal 
mucosa to cancer) ranges from 10.6 to 25.8 years
28
. Even more relevant, one estimate of the mean 
sojourn time of preclinical cancer progressing to a detected cancer ranged from 4.5 to 5.8 years
29
.  
PCCRCs may differ from detected CRCs, including having shorter dwell times; this is possibly why we see 
an excess of rapidly growing right-sided lesions in PCCRCs. Much published data is for left-sided series 
(i.e. flexible sigmoidoscopy data). There was much discussion within the group on this issue and it was 
concluded that using a period of 48 months is a reasonable assumption, whilst being cognisant of the 
uncertainties of the natural history of the disease. 
Whilst arbitrary and undoubtedly imperfect, this definition provides both objectivity and standardization 
to categorization, aiding QA and comparisons between series. 
This 4-year cut-off is used to assign the most plausible etiology. In statement 16, below, a 3-year cut-off 
is used to calculate the PCCRC rate – the reasons for this difference are described in that section. 
Examples of this categorization are provided in the relevant online supplementary document. 
 
Statement 7. To facilitate attribution of PCCRC etiology, we recommend that endoscopy/pathology 
services should collect the following minimum dataset for each procedure: 
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• Date of colonoscopy 
• Patient age 
• Patient sex 
• Procedure indication (screening, surveillance, symptomatic) 
• Predisposing risk factors for CRC (e.g. high-risk cohort such as Ulcerative or Crohn’s colitis or 
hereditary forms of CRC such as Lynch syndrome and familial adenomatous polyposis) 
• Quality of bowel preparation (using a validated score) 
• Extent of exam (including photo-documentation of 2 of 3 cecal hallmarks: appendiceal orifice, 
ileocecal valve, terminal ileum)  
• Location of all visualized polyps 
• Estimated size of all visualized polyps 
• Paris classification of all visualized polyps by segment of colon 
• Type of endoscopic resection (cold snare, cold biopsy, hot biopsy, hot snare, EMR, ESD) 
• Completeness of polyp resection, as judged by the endoscopist (not resected, incompletely 
resected, completely resected). State if the lesion is excised en-bloc or in a piecemeal fashion. 
• Completeness of polyp resection, as judged by the histopathologist (not assessed/not 
assessable, incompletely resected, completely resected) and supported by photo-
documentation. State if the lesion is received fragmented or en-bloc 
• Other colonic pathology (such as diverticulosis or inflammatory bowel disease) 
• Post-procedure management plan 
 GRADE of evidence: low; Strength of recommendation: strong. 
 
Statement 8. We recommend that other endoscopist-related performance measures, such as cecal 
intubation rates, adenoma detection rates and cecal withdrawal times, are routinely collected by the 
endoscopy service, and are used to assist in the review of PCCRC cases. 
GRADE of evidence: low; Strength of recommendation: strong. 
To facilitate attribution of PCCRC etiology and associated performance measure metrics30, the routine 
capture of a minimum dataset is required. Most of these items should be incorporated into routine 
procedural documentation, through an electronic endoscopy reporting system.  
• Modality of endoscopic resection (cold snare, cold biopsy, hot biopsy, hot snare, EMR, ESD) 
• Cecal intubation (including photo-documentation, e.g. at least 2 quality images to document 2 
of the 3 landmarks: ileocecal valve, appendiceal orifice, terminal ileum)  
• Quality of bowel preparation (using a validated score) that assesses prep quality after all efforts 
to clean the colon wall 
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• Polyp sizes, measured against the known diameter of biopsy forceps or a snare to minimise 
inter-observer variation 
• Although imperfect, the Paris polyp classification
(22)
 is the most standardized morphology 
categorization available and endoscopists should be encouraged to use it, either in descriptive 
terms (e.g. flat lesion with depressed component) or in Paris “shorthand” (e.g. Paris 0-IIa/c). As a 
“next best option”, in cases where endoscopists are not entirely comfortable with the full Paris 
classification, the morphology of each polyp should be characterized as sessile, pedunculated, or 
flat. 
 
• Polyp location using the nine cardinal colon segments (i.e. cecum, ascending colon, hepatic 
flexure, transverse colon, splenic flexure, descending colon, sigmoid colon, rectosigmoid colon 
and rectum). 
 
• Polypectomy details including 
o Polypectomy instrument (snare, biopsy forceps, etc) 
o Use of electrocautery (yes/no; electrocautery machine; settings) 
o Special technique (e.g. EMR, ESD) 
o Piecemeal or en-bloc excision 
o Completeness of resection (endoscopically and histologically) 
To ensure complete polypectomy, clear demarcation of the lesion (use digital chromoendoscopy if 
needed) should be achieved before resection ideally in a single-piece fashion, and close inspection 
should be performed after resection. 
We suggest monitoring both endoscopist factors (i.e. cecal intubation rates
10
, ADR or polyp detection 
rate 
14, 18, 31, 32
, withdrawal time
33
 and associated patient factors (i.e. patient age, significant 
comorbidities, diverticular disease)
34
. 
 
Statement 9. To facilitate detailed descriptions of PCCRC, we recommend that clinical and pathology 
services should collect the following minimum dataset for each CRC: 
• Was the CRC detected in the context of screening, surveillance or a symptom-driven 
procedure? 
• Date and type of previous colorectal imaging prior to the episode of care in which CRC was 
detected 
• Tumor location 
• Macroscopic appearance (e.g. pedunculated, exophytic, ulcerated or diffusely infiltrating) 
• Tumor size (horizontal or width in mm) 
• Histologic type 
• Tumor grade (low/high) 
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• Microscopic tumor extension (pT) 
• Number of regional lymph nodes evaluated/number of positive lymph nodes (pN) 
• Vascular lymphatic invasion 
• Perineural invasion 
• Tumor budding (where recommended, see below) 
• Tumor deposits  
• Resection margins  
GRADE of evidence: low; Strength of recommendation: strong. 
Screening programs and studies on PCCRC should include the standard parameters that are 
recommended in consensus documents such as the Royal College of Pathologists, the Nationwide 
Network and Registry of Histology and Cytopathology in the Netherlands (PALGA), the NHS Bowel 
Cancer Screening Program in the UK or the American College of Pathologists
35-37
. 
The minimum dataset or core data items for colorectal cancer histopathology report are: type of 
excision, location, tumor size, histological tumor type, histological differentiation, local invasion (pT), 
tumor budding, lymph node status (pN), stage, vascular invasion, resection margins, tumor deposits, 
other abnormalities or lesions, and presence/absence of metastases (pM) when biopsy material from a 
metastatic lesion is available
38
. 
Additional data items, considered by some authors as non-core are: nature of invasive margin 
(expansive, infiltrating or both), specimen length, macroscopic intactness of mesorectum, intra and 
peritumoral lymphocytic response, 
25, 35, 37, 39-43
. 
Tumor budding is defined as a single tumor cell or a cell cluster consisting of 4 tumor cells or less. Tumor 
budding is counted on Hematoxylin-Eosin. The hot spot method (in a field measuring 0.785mm
2
 at the 
invasive front) is recommended
44
. A three-tier system should be used along with the budding count in 
order to facilitate risk stratification in CRC. Tumor budding is an independent predictor of lymph node 
metastasis in pT1 CRC, and is an independent predictor of survival in stage II CRC
44
. Tumor budding 
should be taken into account along with other clinicopathological features in a multidisciplinary setting. 
Tumor budding and tumor grade are not the same
45
. 
Photo-documentation of the surgical resection specimens is recommended. The macroscopic 
appearance of the tumour in the surgical specimen can provide complementary information that may, 
together with microscopic appearance and other factors, help to correctly classify the tumour. 
 
Statement 10. We recommend that MSS/MSI status should be assessed on all PCCRC cases either by 
immunohistochemistry or PCR. RAS mutations, BRAF mutations, or other targetable molecular 
alterations should be determined when indicated.  
GRADE of evidence: low; Strength of recommendation: strong. 
Given PCCRCs are not always due to procedural factors, all services should consider examining molecular 
features associated with a more rapid progression to cancer. 
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MMR proteins or MSI status should be performed on all CRCs or at minimum all CRCs diagnosed at age 
less than 70. Detection of defective MMR in CRCs can be used to cost effectively screen CRC patients for 
possible Lynch syndrome, which accounts for approximately 2% to 3% of all CRC. Lynch syndrome 
diagnosis has prognostic and therapeutic implications which include genetic family assessment and 
counselling 
46
.  
Patients with a microsatellite instability-high (MSI-H) phenotype indicates that mismatch repair 
deficiency in their cancer may be sporadic or have a germline mutation in one of several DNA mismatch 
repair (MMR) genes (eg, MLH1, MSH2, MSH6, or PMS2) or an altered EPCAM (TACSTD1) gene. For 
tumors with immunohistochemical loss of expression for MLH1, testing for BRAF gene mutation (V600E) 
or MLH1 methylation analysis is indicated
47
. Approximately 15% of sporadic CRC are MSI. BRAF gene 
V600E mutation is not present in hereditary cancers, and loss of MLH1 is mostly due to a germline 
mutation and genetic testing should be performed. Loss of MSH2 or MSH6 expression strongly suggests 
Lynch syndrome. PMS2 loss is often associated with loss of MLH1 and is only independently meaningful 
if MLH1 is intact.  
K-N-RAS and BRAF mutations, or other targetable molecular alterations should be determined when 
appropriate.  
Current recommendations from the American Gastroenterology Association and the NCCN recommend 
patients with stage IV colorectal carcinoma who are candidates for anti-EGFR antibody therapy should 
have their tumor tested for K-N-RAS and BRAF mutations43. 
 
QUANTITATIVE ASSESSMENT: PCCRC RATE 
 
This section outlines the recommended methodology for assessing PCCRC rates across services. 
 
Statement 11. The PCCRC rate is an important performance measure of the ability of colonoscopy to 
detect and prevent CRC. We recommend that it should be used to monitor the quality of a 
colonoscopy service. 
GRADE of evidence: very low; Strength of recommendation: strong. 
The PCCRC rate of a colonoscopy service determines its efficacy in detecting and preventing cancer and 
should, therefore, be the principal measure of quality in colonoscopy, driving performance improvement 
within the service. Monitoring PCCRC rates facilitates benchmarking and comparison between 
endoscopy services. A powerful method for quality improvement is to have a minimum performance 
standard and as performance improves, to raise the bar periodically. Where there is no well-defined 
minimum standard, funnel plots can be used to identify outliers, as described below. 
Patients and payers of health care increasingly want to know how they might improve outcomes and 
achieve best value for money
9
. The PCCRC rate can provide a benchmark measure to compare 
performance to facilitate payer and patient choice, as well as to inform decisions for system-wide 
quality improvement interventions. In an ideal system, a low PCCRC rate would be incentivised. The 
PCCRC rate may also be used to support decisions for system-wide quality improvement interventions - 
for example, if an intervention were known to reduce PCCRC rate it would be possible to predict a cost 
of reducing one PCCRC using that intervention. 
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Surrogate measures of colonoscopy quality, such as cecal intubation rate, adenoma detection rate and 
withdrawal time are easier to capture than PCCRC rate
48-51
; however, they are only surrogates of the 
true outcome that matters most to patients, i.e. a post-colonoscopy cancer
52
. 
Statement 12. We recommend that the PCCRC rate should only be used to benchmark services if the 
required data quality and the necessary databases linkages are available.  
GRADE of evidence: low; Strength of recommendation: strong. 
Statement 13. We recommend that PCCRC rates should be externally reported at a service level, 
rather than for individual endoscopists. We recommend that PCCRC rates should be displayed with 
95% confidence intervals, and, where appropriate, plotted on a funnel plot to identify outliers more 
readily. 
GRADE of evidence: low; Strength of recommendation: strong. 
The calculation of PCCRC rates is complex - calculation cannot simply rely on the colonoscopy service, 
but rather requires a collaborative approach within a multidisciplinary healthcare system, including 
epidemiologists and cancer registries, with agreed data collection, adherence to confidentiality 
requirements and oversight by experts. Clinical services should be cautious about publishing their PCCRC 
rate, unless they are confident about the quality and completeness of the data. For example, patients 
may move from their catchment area precluding capture of subsequent cancer, leading to a false 
reassurance of a low rate. Only linkage of population-based databases can provide accurate rates for 
comparison between services. If comprehensive and accurate colonoscopy and cancer databases are not 
in place, then it is impossible to calculate an accurate rate
53
. 
Large sample sizes of cancer are required to provide estimates of PCCRC rate with sufficient precision: 
rates will not be interpretable for small samples19. 
From this example (Table 5), assuming a 3% CRC yield at colonoscopy and a mean PCCRC of 8.6%, 9,967 
colonoscopies would be required to have 80% power to detect poor performance (based on 
unacceptable PCCRC rate of 12.9%, i.e. 50% more than the mean); or 2,767 colonoscopies if based on 
unacceptable figure of 17.2% (100% more than mean). Thus, although calculating individual PCCRC rates 
is inaccurate due to imprecision, a root cause analysis should routinely be performed on every PCCRC 
case and discussed with the colonoscopist who performed the original colonoscopy. 
Funnel plots of estimates provide a visual method of determining whether there is sufficient sample size 
to rely on the estimate of PCCRC rate calculated from the sample and to use confidence intervals to 
estimate uncertainty. 
 
Statement 14. Whilst for epidemiological and research purposes, there remains a benefit in 
performing various analyses of PCCRC-related data, we suggest that for quality assurance purposes, a 
standardized method to calculate an unadjusted PCCRC rate should be used to permit the 
benchmarking of services. We recommend that this “unadjusted PCCRC rate” is calculated as the 
number of PCCRCs divided by the total of the number of PCCRCs plus the number of detected cancers, 
expressed as a percentage. 
GRADE of evidence: very low; Strength of recommendation: strong. 
To date, no two published studies have used the same methodology for calculating PCCRC rate. Morris 
et al demonstrated that PCCRC rates, using the same data, vary from 2.5% to 7.7%, depending on the 
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methodology used. Having a single method to calculate rates will enable more reliable comparisons of 
rates between studies and jurisdictions
19
.  
A CRC may be both a detected cancer (if it was diagnosed by colonoscopy within 6 months) and a PCCRC 
(if there was also a prior colonoscopy between 6 and 36 months ago) - in which case the one cancer will 
contribute to both categories - excluding such cases from the PCCRC count, as some previous studies 
have done, will markedly decrease the PCCRC rate. 
The unadjusted PCCRC rate described has the advantage of being clinically relevant, simpler to calculate 
and, at least from a methodological perspective (1-sensitivity), is unaffected by the prevalence of CRC in 
the population undergoing colonoscopy. Practices with highly atypical patient populations (e.g. solely 
colitis surveillance patients) might not be suitable for benchmarking PCCRC rates. Modest data exist for 
using a PCCRC rate as a performance measure. Therefore, additional research exploring different 
methodologies and their correlations with other performance measures is needed. Examples of other 
calculations include PCCRCs per 100,000 person-years’ follow-up, and PCCRCs per 1000 persons 
diagnosed within a defined time-period since the last negative colonoscopy. This method has the 
advantage that it reflects persons-time AT RISK and accounts for loss to follow-up54, and is in line with 
the method proposed within the “Europe Against Cancer” Program” (EACP)55, a standard methodology 
for describing interval cancers in other screening programs. This method would typically require linking 
a defined cohort of subjects with a negative colonoscopy to a comprehensive population-based cancer 
registry. 
When comparing PCCRC rates, age standardization, adjustment for time period of measurement and 
stratification by sex may be considered given the potential variation in these cancer risk factors between 
cohorts. 
The proportionate interval cancer incidence (also called the proportional incidence method) aims to 
overcome the challenge of variation in risk factors between cohorts by evaluating interval cancer 
incidence against the background incidence. This is calculated by dividing the observed number of 
interval cancers during a given period by the (estimated) cancer incidence expected in the absence of 
screening during that period. In other screening programs, the proportionate interval cancer incidence 
has been used to compare sensitivity between different settings
56
, for example, breast cancer screening 
and fecal occult blood testing. However, its applicability to PCCRCs is not known and further 
methodological research is required (see online supplementary material). 
 
Statement 15. We recommend that the unadjusted PCCRC rate is calculated based on the date the 
person had the colonoscopy, with the term “detected cancer” being used to describe cancers 
diagnosed by the colonoscopy or within 6 months of the date of the colonoscopy, and the term “post-
colonoscopy colorectal cancer” (PCCRC) used to describe cancers identified beyond 6 months of the 
date of the colonoscopy. 
GRADE of evidence: very low; Strength of recommendation: strong.  
If a colonoscopy is of inadequate quality to exclude cancer or a polyp because of poor colon cleansing or 
inability to inspect the entire colon, a repeat procedure or other investigation is usually scheduled. In 
other situations, biopsies may not detect a cancer suspected at the time of colonoscopy, but a cancer is 
confirmed at subsequent surgery. To avoid inappropriately assigning such delays to the colonoscopy, 
and to allow time for linkages of regional databases, a 6-month period of grace is considered a 
pragmatic solution to permit complex cases to be diagnosed
19, 34
. 
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Although this may misclassify a small number of cancers actually missed on an initial complete 
colonoscopy, and subsequently spotted in a colonoscopy performed within 6 months due to, for 
example, ongoing symptoms, we expect these cases to be exceptions rather than the rule.  
Further qualitative research is required before a different interval can be proposed.  
 
Statement 16. We suggest that when the unadjusted PCCRC rate is calculated, the follow-up period 
since the last colonoscopy is denoted with a suffix –Ny where N refers to the number of years’ follow-
up after the last colonoscopy. For consistency and to permit benchmarking, we recommend that as a 
minimum, all services should report the PCCRC rate for an interval of 3 years (PCCRC-3y). 
GRADE of evidence: low; Strength of recommendation: weak. 
Regardless of the quality of colonoscopy, the number of PCCRCs detected will increase over time – rates 
for a 3-year period will differ from a 10-year period. Given our current paucity of knowledge, there is 
value in reporting rates after different follow-up periods; however, when PCCRC is used as a benchmark 
to compare services the rate needs to be defined for a set follow-up period.   
Our panel’s consensus was that this should be set at 3 years – this decision takes into account various 
factors, including: 
1. an adequate sample size for statistical purposes; 
2. the need to reflect contemporaneous (rather than historical) practice as much as possible; 
3. cancer biology and sojourn times  
It is important to understand that this 3-year cut-off relates to the calculation of PCCRC rate and has 
been recommended for the reasons stated above. It is distinct from the use of a 4-year cut-off when 
reviewing a PCCRC to determine the most plausible etiology, which relates more to a lesion’s biology, as 
described in statement 6. Ideally, the PCCRC-1 year, PCCRC-5 year and PCCRC-10 year rates should be 
also calculated, to develop an evidence-base for various time cut-offs. 
Precise methodology for PCCRC-3y rate calculation is given below: 
• Identify all people undergoing a colonoscopy in a certain year 
• Each colonoscopy is labelled according to the outcome of the test:  
o True positive colonoscopy (where a CRC was detected at that procedure, or within 6 
months – a “detected CRC”) 
o False negative colonoscopy (where a CRC was detected between 6 and 36 months of 
the procedure – a “PCCRC”)  
o True negative colonoscopy (No CRC detected within 36 months of the procedure) 
• Note: 
o A person may have had several tests within each time period. However, only one true 
positive and one false negative test should be included for each CRC:    
 Only the closest true positive test to the CRC diagnosis should be included  
 Only the closest false negative test should be included; any further false 
negative tests should be re-classified as true negative tests 
o A person may also have been diagnosed with more than one CRC. Each colonoscopy 
should only be included once and should relate to the closest subsequent CRC 
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• The PCCRC-3y rate is then calculated as: False negatives / (True positives + False negatives) % 
It should be noted that PCCRC nomenclature is designed for colorectal adenocarcinoma; cancers for 
which colonoscopy is not considered “gold standard” for their diagnosis (for example, neuroendocrine 
tumours, or squamous cell carcinomas of the anorectum) should not be included. Likewise, given that 
adenocarcinoma of the appendix may not be apparent endoscopically, we recommend that these are 
not included. 
Statement 17. Where exclusions in the population on which PCCRC is calculated are felt to be 
necessary, these should be stated explicitly in the methodology. However, we recommend that a 
PCCRC rate involving the entire cohort of adult patients, without exclusions, is also provided. 
GRADE of evidence: very low; Strength of recommendation: strong. 
When large scale populations are studied, it is unlikely that small cohorts of high-risk patients will 
significantly affect PCCRC rates significantly; thus, inclusion of all CRC patients is encouraged. It is 
recognised, however, that various services may opt to exclude such cohorts to their PCCRC calculation.  
High-risk CRC cohorts, for whom more frequent surveillance is recommended
57-59
 include patients with 
previous CRC or advanced/multiple colonic polyps 
57, 58, 60-63
, Lynch syndrome
57
 and longstanding 
extensive colitis
59
, where there is possibly a different dysplasia-carcinoma pathway or an accelerated 
adenoma-carcinoma pathway that might influence the appearance of premalignant lesions and the 
speed of development into cancer
64, 65
. 
 
 
 
 
 
NON-COLONOSCOPIC IMAGING OF THE COLON 
 
Statement 18. We recommend that in the wider context of all colorectal imaging investigations, Post-
Imaging Colorectal Cancer (PICRC) is the preferred term for cancers appearing after a colorectal 
imaging investigation that is negative for CRC. Similar to PCCRC, PICRC should be used to describe 
cancers identified beyond 6 months of the date of the imaging procedure. 
GRADE of evidence: very low; Strength of recommendation: strong. 
Although colonoscopy is currently the most frequent method for investigating the colon, it is not the 
only colonic investigation. Currently Computerised Tomographic Colonography (CTC) is the only widely 
available alternative to colonoscopy, but other technologies such as capsule endoscopy are emerging. 
Therefore, to future-proof the terminology, it is proposed that the term “Post-Imaging Colorectal 
Cancer” (PICRC) can be used to extend the applicability of the term beyond colonoscopy to all colonic 
imaging techniques.  
We believe radiology would benefit greatly from such a framework, and it makes sense for the 
definitions, timeframe, caseload requirements, sample size, methodology etc. to be aligned as far as 
possible with colonoscopy. The current focus should be CTC since Barium Enema is essentially a 
historical examination
66
.  
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Statement 19. Whilst it may be possible to calculate PICRC rates across different services using a 
particular colonic imaging technique, such as CTC, we suggest that it is potentially misleading to use 
PICRC rate to compare between different colonic imaging technique, for example to compare CTC and 
colonoscopy, unless the populations being investigated are well-matched or randomized. If this is 
impossible, comprehensive adjustment for all known covariate factors associated with PICRC should 
be undertaken. The same methodological and sample size considerations described for colonoscopy 
should also be applied for radiological imaging. 
GRADE of evidence: low; Strength of recommendation: weak. 
There are relatively few studies reporting long-term PICRC rates for CTC
66-71
. A recent systematic review 
found only 12 studies regarding this topic, reporting on just under 20,000 patients, with a pooled PICRC 
rate of 4.4% at average follow-up of 3 years
72
. Although this rate is comparable to that reported for 
colonoscopy, these data were mostly derived from either research trials or single-centre audits, with no 
large-scale series encompassing the routine clinical practice of an entire healthcare system.  
 
Since CTC and colonoscopy are often applied in differing clinical scenarios, with CTC commonly being 
reserved for patients who are either deemed unsuitable for colonoscopy or in whom it has failed, there 
are likely to be substantial differences between the populations undergoing each examination. This is 
likely to translate to different PICRC rates irrespective of the diagnostic accuracy of the two techniques. 
The same methodological and sample size considerations described for colonoscopy (above) should also 
be applied for CTC. 
 
 
 
Statement 20. To facilitate adjudication of PICRC case etiology, we recommend that radiology services 
should collect the following minimum dataset for all radiology procedures.  
ESSENTIAL: 
• Date of procedure 
• Type of procedure  
• Imaging site name / code 
• Indication for colonic examination  
• Reason for use of radiological examination rather than colonoscopy  
• Bowel cleansing agent used, dose, and quality of cleansing 
• Fecal tagging agent used, dose, and quality of tagging 
• Gas used for and quality of colonic distension 
• Patient positioning during image acquisition 
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• Findings in each colonic segment 
o Details of polyps/cancers found if applicable (number, size, morphology) 
DESIRABLE:  
• Details on interpreter(s) of images (name, lifetime experience, number of cases interpreted in 
previous 24 months) 
• CT image acquisition details (slice thickness/reconstruction interval/dose parameters) 
• Use of intravenous contrast and antispasmodic 
• Mode of interpretation and use of Computer Assisted Detection (CAD) 
• Subsequent management recommendations 
o Discharge/repeat examination/refer for endoscopy/surgery/other 
o If referral for endoscopy, relevant minimum dataset to be completed 
o If repeat radiology what was the recommended/actual interval 
GRADE of evidence: low; Strength of recommendation: strong. 
 
Statement 21: We recommend that if a PICRC is diagnosed, the following data should be sought 
retrospectively, including by review of CTC images.  
ESSENTIAL 
Findings in segment of colon where PICRC was subsequently found (number, size, morphology and 
histology of polyps/cancers; presence/absence of diverticular disease; other colonic diagnoses). 
• Actual patient management, and any difference from that originally recommended at the time 
of CTC reporting. 
• Impression of the likely nature of the missed lesion (technical error, perceptual/reader error, 
non-diagnosable/” invisible” lesion, unknown). 
DESIRABLE 
• Findings in the remainder of the colon (i.e. segments other than where the PICRC was 
diagnosed). 
• Details on interpreter(s) of images (positive predictive value over last 24 months, polyp 
detection rate for proven adenomas 6mm+ over last 24 months). 
GRADE of evidence: very low; Strength of recommendation: strong. 
Individuals undergoing radiological examination are often selected for imaging on the basis of suitability 
or otherwise for colonoscopy. The factors that make colonoscopy difficult or impossible (e.g. diverticular 
disease) may also increase the risk of PICRC. It is therefore important to record the spectrum of patients 
referred for imaging to permit meaningful interpretation of PICRC rates
4, 19, 73, 74
.  
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There are no published data linking radiologist performance to PICRC rates. However, experience and 
case volume are associated with higher diagnostic sensitivity in some studies, and with higher detection 
rates in observational studies, meaning it is plausible that PICRC rate is operator-dependent
75-77
. 
If PICRCs are detected, it is highly desirable to re-examine the entire imaging dataset in an attempt to 
determine the underlying reasons for PICRC. We recognize that this may not be possible, e.g. if CTC 
images have been deleted; nevertheless, such data should still be sought wherever practicable. Missed 
lesions at CTC (e.g. during diagnostic test accuracy studies) are classified variably in the literature, but a 
common scheme is (a) technical error (i.e. part of the scanned volume cannot be adequately evaluated, 
for example due to poor colonic distension, or retained untagged stool); (b) perceptual or reader error 
(i.e. in retrospect, an abnormality-a polyp or cancer- is visible on the CTC images, and was overlooked by 
the reader at the time of scan reporting); and (c) truly non-diagnosable / “invisible” lesions (i.e. CTC may 
be deemed normal, even in retrospect. In the context of PICRC, the final category will include some 
polyps that are non-detectable at CTC (e.g. too small, or completely flat) and some new lesions (e.g. CRC 
developing via a rapid carcinogenesis pathway)
78-81
. Ideally, such review should be performed by an 
experienced, independent CTC radiologist. 
5. RESEARCH PRIORITIES 
 
A proposed checklist for peer review of future papers on the topic is available as online supplementary 
material.  
We consider the following list to be the key research questions: 
• What is the natural history of adenomas and serrated lesions? 
• How does natural history of adenomas and serrated lesions differ in the proximal/distal colon? 
• What is the natural history of CRC, including the sojourn time of stages and of the preclinical 
phase? 
• How does natural history of CRC differ in the proximal/distal colon? 
• How can the above be used to refine etiology categorization? 
• To what extent do different methodologies for the calculation of PCCRC rates correlate with, 
add to, or improve on the methodology in this manuscript? 
• To what extent does PCCRC rate correlate with other colonoscopy performance measures? 
• Can qualitative research of the pathways to the point of CRC diagnosis help refine the current 6- 
month cut-off between detected CRCs and PCCRCs? 
• Validation of the recommended method of reporting a PCCRC rate 
• To what extent is a PCCRC-1y rate predictive of a PCCRC-3y rate? 
• What are the strengths and weaknesses of different methodologies (e.g. number of PCCRCs 
expressed per 100,000 person-years’ follow-up, number of PCCRCs diagnosed within a defined 
time-period since the last negative colonoscopy per 1000 persons with a negative colonoscopy)? 
Can these be correlated with other performance measures? 
• Would including large (10mm+) polyps in the calculate of a missed lesion rate be advantageous? 
• What information from the pathology report is useful to identify a hig-risk patient?  
• To what extent can PCCRC rate calculation be automated? 
• Can electronic endoscopy reporting systems be modified to capture key data? 
• What are the PCCRC rates in special groups such as those with IBD or hereditary CRC syndrome? 
• What are the most effective interventions to reduce unwarranted variation in PCCRC rates? 
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• Which screening modalities are most effective at minimizing PCCRC, in particular in relation to 
the serrated pathway? 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
REFERENCES 
 
1. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-
to-back colonoscopies. Gastroenterology 1997;112:24-8. 
2. van Rijn JC, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy: a 
systematic review. Am J Gastroenterol 2006;101:343-50. 
3. Lakoff J, Paszat LF, Saskin R, et al. Risk of developing proximal versus distal colorectal cancer 
after a negative colonoscopy: a population-based study. Clin Gastroenterol Hepatol 
2008;6:1117-21; quiz 1064. 
4. Bressler B, Paszat LF, Chen Z, et al. Rates of new or missed colorectal cancers after colonoscopy 
and their risk factors: a population-based analysis. Gastroenterology 2007;132:96-102. 
5. Govindarajan A, Rabeneck L, Yun L, et al. Population-based assessment of the outcomes in 
patients with postcolonoscopy colorectal cancers. Gut 2015. 
6. Rabeneck L, Paszat LF, Saskin R. Endoscopist specialty is associated with incident colorectal 
cancer after a negative colonoscopy. Clin Gastroenterol.Hepatol. 2010;8:275-279. 
7. Sanduleanu S, le Clercq CM, Dekker E, et al. Definition and taxonomy of interval colorectal 
cancers: a proposal for standardising nomenclature. Gut 2015;64:1257-67. 
8. Leddin D, Enns R, Hilsden R, et al. Colorectal cancer surveillance after index colonoscopy: 
guidance from the Canadian Association of Gastroenterology. Can J Gastroenterol 2013;27:224-
8. 
9. Rabeneck L, Paszat LF. Circumstances in which colonoscopy misses cancer. Frontline 
Gastroenterol 2010;1:52-58. 
10. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from 
colorectal cancer. Ann Intern Med 2009;150:1-8. 
11. Baxter NN, Sutradhar R, Forbes SS, et al. Analysis of administrative data finds endoscopist 
quality measures associated with postcolonoscopy colorectal cancer. Gastroenterology 
2011;140:65-72. 
12. Arain MA, Sawhney M, Sheikh S, et al. CIMP status of interval colon cancers: another piece to 
the puzzle. Am J Gastroenterol 2010;105:1189-95. 
13. Sanduleanu S, Masclee AM, Meijer GA. Interval cancers after colonoscopy-insights and 
recommendations. Nat Rev Gastroenterol Hepatol 2012;9:550-4. 
14. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and 
death. N Engl J Med 2014;370:1298-306. 
15. Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during colonoscopy-results of 
the complete adenoma resection (CARE) study. Gastroenterology 2013;144:74-80.e1. 
16. Lieberman DA, Holub JL, Moravec MD, et al. Prevalence of colon polyps detected by 
colonoscopy screening in asymptomatic black and white patients. Jama 2008;300:1417-22. 
17. Soetikno RM, Kaltenbach T, Rouse RV, et al. Prevalence of nonpolypoid (flat and depressed) 
colorectal neoplasms in asymptomatic and symptomatic adults. Jama 2008;299:1027-35. 
18. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of 
interval cancer. N Engl J Med 2010;362:1795-803. 
19. Morris EJ, Rutter MD, Finan PJ, et al. Post-colonoscopy colorectal cancer (PCCRC) rates vary 
considerably depending on the method used to calculate them: a retrospective observational 
population-based study of PCCRC in the English National Health Service. Gut 2015;64:1248-56. 
20. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, 
reporting and evaluation in health care. Cmaj 2010;182:E839-42. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
24 
 
21. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of 
evidence and strength of recommendations. BMJ 2008;336:924-6. 
22. Pabby A, Schoen RE, Weissfeld JL, et al. Analysis of colorectal cancer occurrence during 
surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc 2005;61:385-
91. 
23. Huang Y, Gong W, Su B, et al. Risk and Cause of Interval Colorectal Cancer after Colonoscopic 
Polypectomy. Digestion 2012;86:148-154. 
24. Robertson DJ, Lieberman DA, Winawer SJ, et al. Colorectal cancers soon after colonoscopy: a 
pooled multicohort analysis. Gut 2014;63:949-56. 
25. le Clercq CM, Bouwens MW, Rondagh EJ, et al. Postcolonoscopy colorectal cancers are 
preventable: a population-based study. Gut 2014;63:957-63. 
26. le Clercq CM, Sanduleanu S. Interval colorectal cancers: what and why. Curr Gastroenterol Rep 
2014;16:375. 
27. Chen TH, Yen MF, Lai MS, et al. Evaluation of a selective screening for colorectal carcinoma: the 
Taiwan Multicenter Cancer Screening (TAMCAS) project. Cancer 1999;86:1116-28. 
28. Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, et al. A systematic comparison of microsimulation 
models of colorectal cancer: the role of assumptions about adenoma progression. Medical 
decision making : an international journal of the Society for Medical Decision Making 
2011;31:530-9. 
29. Brenner H, Altenhofen L, Katalinic A, et al. Sojourn time of preclinical colorectal cancer by sex 
and age: estimates from the German national screening colonoscopy database. Am J Epidemiol 
2011;174:1140-6. 
30. Kaminski MF, Thomas-Gibson S, Bugajski M, et al. Performance measures for lower 
gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) quality 
improvement initiative. United European Gastroenterol J 2017;5:309-334. 
31. Chiu SY, Chuang SL, Chen SL, et al. Faecal haemoglobin concentration influences risk prediction 
of interval cancers resulting from inadequate colonoscopy quality: analysis of the Taiwanese 
Nationwide Colorectal Cancer Screening Program. Gut 2015. 
32. Baxter NN, Warren JL, Barrett MJ, et al. Association between colonoscopy and colorectal cancer 
mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol 
2012;30:2664-9. 
33. Shaukat A, Rector TS, Church TR, et al. Longer Withdrawal Time Is Associated With a Reduced 
Incidence of Interval Cancer After Screening Colonoscopy. Gastroenterology 2015;149:952-7. 
34. Singh S, Singh PP, Murad MH, et al. Prevalence, Risk Factors, and Outcomes of Interval 
Colorectal Cancers: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2014. 
35. Reporting Lesions in the NHS Bowel Cancer Screening Programme: the NHS BCSP Publication 1, 
2007. 
36. Pathologists RCo. Standards and Datasets for Reporting Cancers — Dataset for Colorectal Cancer 
Histopathology Reports. 3rd edition, 2014. 
37. Pathologists CoA. College of American Pathologists. Protocol for the examination of specimens 
from patients with primary carcinoma of the colon and rectum., 2013. 
38. AJCC Cancer Staging Manual, Eighth Edition, 2016. 
39. Quirke P, Risio M, Lambert R, et al. Quality assurance in pathology in colorectal cancer screening 
and diagnosis-European recommendations. Virchows Arch 2011;458:1-19. 
40. Vieth M, Quirke P, Lambert R, et al. Annex to Quirke et al. Quality assurance in pathology in 
colorectal cancer screening and diagnosis: annotations of colorectal lesions. Virchows Arch 
2011;458:21-30. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
25 
 
41. Hamilton SR BF, Boffetta P, Ilyas M, Morreau H, Nakamura, S-I QP, Riboli E, Sobin LH. Carcinoma 
of the colon and rectum. IN: Bosman FT, World Health Organization, International Agency for 
Research on Cancer. editors. WHO classification of tumours of the digestive system. Lyon: 
International Agency for Research on Cancer, 2010, p134-46:  
42. Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer--ready for diagnostic practice? 
Hum Pathol 2016;47:4-19. 
43. Benson AB, 3rd, Venook AP, Cederquist L, et al. Colon Cancer, Version 1.2017, NCCN Clinical 
Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:370-398. 
44. Koelzer VH, Zlobec I, Berger MD, et al. Tumor budding in colorectal cancer revisited: results of a 
multicenter interobserver study. Virchows Arch 2015;466:485-93. 
45. Lugli et al. Recommendations for reporting tumour budding in colorectal cancer based on the 
International Tumor Budding Consensus Conference. Virchows Archiv 2016;469-Suppl 1: S172. 
PS-16-116. 
46. Rubenstein JH, Enns R, Heidelbaugh J, et al. American Gastroenterological Association Institute 
Guideline on the Diagnosis and Management of Lynch Syndrome. Gastroenterology 
2015;149:777-82; quiz e16-7. 
47. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of 
Lynch syndrome: A consensus statement by the U.S. Multi-Society Task Force on Colorectal 
Cancer. Gastrointestinal Endoscopy;80:197-220. 
48. Jover R, Zapater P, Bujanda L, et al. Endoscopist characteristics that influence the quality of 
colonoscopy. Endoscopy 2016;48:241-7. 
49. von Karsa L, Patnick J, Segnan N, et al. European guidelines for quality assurance in colorectal 
cancer screening and diagnosis: overview and introduction to the full supplement publication. 
Endoscopy 2013;45:51-9. 
50. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Am J Gastroenterol 
2015;110:72-90. 
51. Lee TJ, Rutter MD, Blanks RG, et al. Colonoscopy quality measures: experience from the NHS 
Bowel Cancer Screening Programme. Gut 2012;61:1050-7. 
52. Kaminski MF, Wieszczy P, Rupinski M, et al. Increased Rate of Adenoma Detection Associates 
With Reduced Risk of Colorectal Cancer and Death. Gastroenterology 2017;153:98-105. 
53. Gotfried J, Bernstein M, Ehrlich AC, et al. Administrative Database Research Overestimates the 
Rate of Interval Colon Cancer. J Clin Gastroenterol 2015;49:483-90. 
54. Moss S, Ancelle-Park R, Brenner H, et al. European guidelines for quality assurance in colorectal 
cancer screening and diagnosis. First Edition--Evaluation and interpretation of screening 
outcomes. Endoscopy 2012;44 Suppl 3:SE49-64. 
55. Sankila R, et a. Evaluation and monitoring of screening programmes. Europe against cancer 
programme, 2001. 
56. Bulliard JL, Sasieni P, Klabunde C, et al. Methodological issues in international comparison of 
interval breast cancers. Int J Cancer 2006;119:1158-63. 
57. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and 
surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-89. 
58. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after 
screening and polypectomy: a consensus update by the US Multi-Society Task Force on 
Colorectal Cancer. Gastroenterology 2012;143:844-57. 
59. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in 
inflammatory bowel disease. J Crohns Colitis 2013;7:982-1018. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
26 
 
60. Valentin F, Guarinos C, Juarez M, et al. Endoscopic surveillance in patients with multiple (10-
100) colorectal polyps. Endoscopy 2016;48:56-61. 
61. Jover R, Bretthauer M, Dekker E, et al. Rationale and design of the European Polyp Surveillance 
(EPoS) trials. Endoscopy 2016. 
62. Castells A, Andreu M, Binefa G, et al. Postpolypectomy surveillance in patients with adenomas 
and serrated lesions: a proposal for risk stratification in the context of organized colorectal 
cancer-screening programs. Endoscopy 2015;47:86-7. 
63. Hassan C, Quintero E, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: 
European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2013;45:842-51. 
64. Sanduleanu S, Rutter MD. Interval colorectal cancers in inflammatory bowel disease: the grim 
statistics and true stories. Gastrointest Endosc Clin N Am 2014;24:337-48. 
65. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance 
and management of dysplasia in inflammatory bowel disease. Gastroenterology 2015;148:639-
651.e28. 
66. Halligan S, Wooldrage K, Dadswell E, et al. Computed tomographic colonography versus barium 
enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a 
multicentre randomised trial. Lancet 2013;381:1185-1193. 
67. Atkin W, Dadswell E, Wooldrage K, et al. Computed tomographic colonography versus 
colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer 
(SIGGAR): a multicentre randomised trial. Lancet 2013;381:1194-1202. 
68. Badiani S, Hernandez ST, Karandikar S, et al. CT Colonography to exclude colorectal cancer in 
symptomatic patients. Eur Radiol 2011;21:2029-38. 
69. Kim DH, Pooler BD, Weiss JM, et al. Five year colorectal cancer outcomes in a large negative CT 
colonography screening cohort. Eur Radiol 2012;22:1488-94. 
70. Lung PF, Burling D, Kallarackel L, et al. Implementation of a new CT colonography service: 5 year 
experience. Clin Radiol 2014;69:597-605. 
71. Thomas S, Atchley J, Higginson A. Audit of the introduction of CT colonography for detection of 
colorectal carcinoma in a non-academic environment and its implications for the national bowel 
cancer screening programme. Clinical Radiology 2009;64:142-147. 
72. Obaro A PA, Fanshawe TR, Torres US, Baldwin-Cleland R, Taylor SA, Halligan S, Burling D. Post-
imaging colorectal cancer or interval cancer rates after computed tomographic colonography: A 
systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology [in press] 
2017. 
73. Cooper GS, Xu F, Barnholtz Sloan JS, et al. Prevalence and predictors of interval colorectal 
cancers in medicare beneficiaries. Cancer 2012;118:3044-52. 
74. Singh H, Nugent Z, Demers AA, et al. Rate and predictors of early/missed colorectal cancers after 
colonoscopy in manitoba: a population-based study. Am J Gastroenterol 2010;105:2588-96. 
75. Taylor SA, Halligan S, Burling D, et al. CT colonography: effect of experience and training on 
reader performance. Eur Radiol 2004;14:1025-33. 
76. ESGAR CT Colonography Study Group Investigators. Effect of Directed Training on Reader 
Performance for CT Colonography: Multicenter Study. Radiology 2007;242:152-161. 
77. Plumb AA, Halligan S, Nickerson C, et al. Use of CT colonography in the English Bowel Cancer 
Screening Programme. Gut 2014;63:964-73. 
78. Park SH, Ha HK, Kim MJ, et al. False-negative results at multi-detector row CT colonography: 
multivariate analysis of causes for missed lesions. Radiology 2005;235:495-502. 
79. Doshi T, Rusinak D, Halvorsen RA, et al. CT colonography: false-negative interpretations. 
Radiology 2007;244:165-73. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
27 
 
80. Slater A, Taylor SA, Tam E, et al. Reader error during CT colonography: causes and implications 
for training. Eur Radiol 2006;16:2275-83. 
81. Plumb AA, Fanshawe TR, Phillips P, et al. Small Polyps at Endoluminal CT Colonography Are 
Often Seen But Ignored by Radiologists. AJR Am J Roentgenol 2015;205:W424-31. 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE LEGENDS 
Figure 1. Consensus voting flowchart 
Figure 2. Most plausible PCCRC explanation 
 
TABLE LEGENDS 
Table 1. Overview of the GRADE tool. 
Table 2. PCCRC Subcategories  
Table 3. Root Cause Analysis checklist for PCCRC/PICRCs 
Table 4 - Potential Explanations of PCCRC from different studies 
Table 5. An illustration of sample sizes required for PCCRC rate calculation 
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The GRADE System 
Quality of evidence Strength of recommendation 
High (further research is very unlikely to change 
our confidence in the estimate of effect) 
Strong (when the desirable effects of an 
intervention clearly outweigh the undesirable 
effects, or clearly do not) 
Moderate (further research is likely to have an 
important impact on our confidence in the 
estimate of effect and may change the estimate) 
Weak (when the trade-offs are less certain—either 
because of low quality evidence or because 
evidence suggests that desirable and undesirable 
effects are closely balanced) 
Low (further research is very likely to have an 
important impact on our confidence in the 
estimate of effect and is likely to change the 
estimate) 
 
Very low (any estimate of effect is very 
uncertain) 
 Table 1 
 
 PCCRC subcategories 
Interval type Non-interval type 
type A type B type C 
Detected prior to recommended 
screening/surveillance interval 
Detected at recommended 
screening/surveillance interval 
Detected after recommended 
screening/surveillance interval 
Where no screening/surveillance 
interval had been recommended 
Case Examples (see 
supplementary 
material for further 
examples) 
Patient with 2 small adenomas is 
advised to return for surveillance 
in 5 years. Four years later 
develops anaemia; colonoscopy 
reveals CRC 
Patient with a 15mm adenoma is 
advised to return for surveillance 
in 3 years. On surveillance at 3 
years a CRC is found 
Patient with 3 small adenomas is 
advised to return for surveillance 
in 3 years. Patient misses this, 
returns 4 years later with CRC 
Patient investigated for history of 
change in bowel habit –  
colonoscopy normal. No further 
investigation recommended. 5 
years later patient develops 
symptoms and a colonoscopy 
reveals CRC. 
Possible implication 
other than 
The recommended 
screening/surveillance interval 
The recommended 
screening/surveillance interval 
Reinforces importance of 
adherence to recommended 
Review whether subsequent 
screening/surveillance may have 
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colonoscopy quality 
(note all may relate to 
poor quality index 
colonoscopy) 
may be too long may be too long screening/surveillance intervals been appropriate 
Table 2 
 
PCCRC/PICRC Root Cause Analysis (RCA) Form 
Patient Demographics  
Age (y)  
Gender (M/F)  
High risk cohort? (IBD, hereditary forms of CRC) (Y/N)  
Details of procedure that led to cancer diagnosis  
Procedure date  
Procedure type  
Procedure indication (screening/site-check/surveillance/symptom-driven [state 
symptom]/therapeutic/other abnormal investigation/other/unknown) 
 
Cancer Details  
Location  
Macroscopic appearance (e.g. pedunculated, exophytic, ulcerated or diffusely infiltrating)  
Tumor size (horizontal or width in mm)  
Histologic Type  
Tumor grade (low/high)  
Microscopic tumor extension (pT)  
Number of regional lymph nodes evaluated/number of positive lymph nodes (pN)  
Vascular lymphatic invasion  
Perineural invasion  
Tumor budding (if available)  
Extranodal tumor deposits  
Resection margins  
Treatment planned  
Treatment intent (curative/palliative/unknown)  
TNM stage  
Dukes stage  
Details of preceding procedure  
Procedure date  
Procedure type  
Procedure indication (screening/site-check/surveillance/symptom-driven [state 
symptom]/therapeutic/other abnormal investigation/other/unknown) 
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Unit ID/Name/Location  
Endoscopist ID  
Endoscopist mean withdrawal time (mins) for year of procedure  
Endoscopist ADR (%) for preceding year  
Make/type of endoscope  
Quality of bowel preparation (use validated scale where possible; or 
good/adequate/inadequate/not recorded) 
 
Extent of procedure  
If incomplete, what was the reason (e.g. looping, luminal stricture etc.)  
Photo of cecum if reached  
Retroflexion performed  
Withdrawal time  
Colonoscopy result (cancer/polyps/other abnormality/normal/unknown)  
If polyp(s) found:  
Number of polyps identified  
List the following for each polyp (continue over if required): 
1. Size of polyp (s) (mm) 
2. Site of polyp (s) 
3. Polyp morphology (Paris) 
4. Histological type of polyp (adenoma, serrated etc.) 
5. Dysplasia grade (high, low, none) 
6. Method of polyp removal (cold snare, cold biopsy, hot biopsy, hot snare, piecemeal EMR, en bloc EMR, ESD, not removed) 
7. Completeness of lesion excision (not assessed, incompletely resected, completely resected, not removed) 
Polyp 1  
Polyp 2  
Polyp 3  
Polyp 4  
Polyp 5  
Follow-up plan from preceding procedure  
Follow-up plan (screening/surveillance/site-check endoscopy/refer for therapy/conservative/no 
recommendation given/unknown) 
 
What follow-up interval was recommended?   
Was the follow-up plan (if applicable) adhered to?  
If not, provide reason for deviation:  
For CT Colonography, fill in relevant sections above and also record:  
Fecal tagging  
Iv contrast  
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Final PCCRC categorization (refer to WEO PCCRC categorization)  
What is the most plausible PCCRC etiology? (see etiology algorithm)  
Any deviation from planned management pathway?  
What is the PCCRC subtype? (refer to PCCRC Subcategories table)  
Table 3 
 
Study Incomplete Resection Missed 
Cancer/Lesion 
New Cancer 
Pabby et al,  
2005  
USA (RCT) 
“…occurred at the site of a previous 
adenoma and… 
absence of a suspicion at endoscopy 
for residual neoplasia” 
1. Different from 
the site of a 
previous adenoma 
2. Within 30 
months or less 
(regardless of size 
or stage) 
3. > 30 months and 
had all features of 
an advanced cancer 
1. Different from 
the site of a 
previous 
adenoma 
2. More than 30 
months 
3. No or only one 
feature of 
advanced cancer 
Huang et al,  
2012  
China (Hospital 
Based) 
“occurred at the site of ‘resected 
tumors’ (i.e. adenoma or early 
cancer)” 
1. Different from 
the site of a 
previous adenoma 
2. Within 30 
months or less 
(regardless of size 
or stage) 
3. > 30 months and 
had all features of 
an advanced cancer 
1. Different from 
the site of a 
previous 
adenoma 
2. More than 30 
months 
3. No or only one 
feature of 
advanced cancer 
Robertson et 
al, 2014 
USA (RCT) 
“…had to be a significant adenoma in 
the same segment. If three or more 
years had passed, then and adenoma 
1. No significant 
adenoma in same 
segment on last 
1. No significant 
adenoma in 
same segment 
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≥5 mm in size or with villous histology 
or with high grade dysplasia was 
considered significant. 
If fewer than 3 years had passed, 
then 
an adenoma ≥ 1cm in size, or with 
villous histology or with high 
grade dysplasia was considered 
significant.” 
exam 
2. Within 36 
months or less 
(regardless of size 
or stage) 
on last exam 
2. Greater than 
36 months 
(regardless of 
size or stage) 
Le Clercq et al, 
2014 
The 
Netherlands 
(Population 
based) 
“…cancer diagnosed in the same 
anatomical segment as a 
previously resected advanced 
adenoma” 
1. Different from 
the site of a 
previous advanced 
adenoma 
2. Within 36 
months or less 
(regardless of size 
or stage) 
3. > 36 months and 
had all features of 
an advanced cancer 
1. Different from 
the site of a 
previous 
advanced 
adenoma 
2. Greater than 
36 months 
3. No or only one 
feature of 
advanced cancer 
Table 4 
 
Current PCCRC 
rate 
Example of unacceptably high PCCRC 
rate 
Number of procedures where cancer found necessary to detect poor performance (alpha, 5% 
1-sided) 
    60% power 70% power 80% power 
8.60%
19
 17.20% 42 59 83 
8.60% 12.90% 162 220 299 
Table 5 
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Examples of PCCRC categorization 
Case 1 - Patient with normal colonoscopy (to terminal ileum, good prep) to investigate iron 
deficiency anaemia. No surveillance recommended. Returns a year later with persistent anaemia, 
has repeat colonoscopy; ascending colon CRC found. PCCRC-non-interval type C; Possible missed 
lesion, prior examination adequate 
Case 2 - Patient with colonoscopy 2 years ago for rectal blood loss, reported as negative (adequate 
prep) but cecal pole not reached due to looping. 10-year screening colonoscopy recommended. 
Returns 9 months later with liver metastases; repeat colonoscopy reveals cecal cancer. PCCRC-
interval type; Possible missed lesion, prior examination negative but inadequate 
Case 3 - Patient has en bloc EMR of 20mm Lateral Spreading Tumor-Granular type in the transverse 
colon polyp. Histology states tubulovillous adenoma with low grade dysplasia, “completeness of 
excision cannot be confirmed”. Patient returns in 3 years for surveillance, distal transverse colon 
cancer is found. PCCRC-non-interval type A; Likely incomplete resection of previously identified 
lesion 
Case 4 - Patient with normal colonoscopy (good prep, cecal photo taken) performed to investigate 
loose stool. No surveillance recommended. Returns after 54 months with anaemia, colonoscopy 
reveals sigmoid CRC. PCCRC-non-interval type C; Likely new CRC 
Case 5 - Elderly inpatient has colonoscopy (good prep, terminal ileum photographed) for rectal 
bleeding; 3cm Lateral Spreading Tumor-Granular type villous adenoma seen in rectum. Plan is made 
for outpatient colonoscopy within 4 weeks for polypectomy, but patient develops myocardial 
infarction needing ITU; returns 8 months later with rectal cancer. PCCRC-non-interval type B; 
Detected lesion, not resected, deviation from the planned management pathway 
Case 6 - Patient has screening colonoscopy; nothing abnormal seen to cecum but bowel prep 
inadequate, advised to return in 1 year. Sigmoid CRC is diagnosed at that time. PCCRC-non-interval 
type A; Possible missed lesion, prior examination negative but inadequate 
Case 7 – 53-year old patient undergoes ileo-colonoscopy to investigate diarrhea. Bowel prep good. 
Two 10mm adenomas resected from sigmoid. 3-year surveillance recommended. Reattends in 3 
years and is diagnosed with CRC in ascending colon. PCCRC-non-interval type A; Possible missed 
lesion, prior examination adequate 
Case 8 – Patient undergoes screening CTC, prep is good, 15mm sessile polyp is described in the 
descending colon. Colonoscopy recommended. Patient does not attend his colonoscopy 
appointment. Presents 2 years later with rectal bleeding – colonoscopy reveals descending colon 
CRC. PICRC-non-interval type B; Detected lesion, not resected, deviation from planned 
management pathway 
Case 9 - Patient undergoes screening colonoscopy which diagnoses a 35mm Lateral Spreading 
Tumor-Non-Granular type polyp in transverse colon. The endoscopist removes the lesion piecemeal 
and recommends follow-up at 3 months. Because of logistical issues (i.e. long waiting list) the patient 
undergoes colonoscopy 10 months later, where cancer is found at the EMR site. PCCRC-non-interval 
type B; Likely incomplete resection of previously identified lesion, deviation from the planned 
management pathway 
Case 10 – 82-year-old with significant comorbidities undergoes colonoscopy (good prep) for iron 
deficiency anaemia. 30mm Lateral Spreading Tumor-NG identified in cecum. Options discussed with 
patient, who chooses conservative management. Patient presents 3 years later with symptomatic 
cecal CRC. PCCRC-non-interval type C; Detected lesion, not resected 
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Case 11 - Patient participates in a colonoscopy screening program. Colonoscopy shows no 
abnormalities (complete but prep is inadequate). 10-year follow-up advised. 1 year later patient 
presents with rectal blood loss. Colonoscopy shows an early depressed carcinoma in the 
rectosigmoid. PCCRC-interval type; Possible missed lesion, prior examination negative but 
inadequate 
 
